ACADIA PHARMACEUTICALS INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $48.87 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-04
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $48.87M, a 219.69% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $43.56M, a 264.17% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $35.58M, a 575.36% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $30.48M, a 31317.53% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $124.90M, a 620.85% increase from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $17.33M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $48.87M 10-Q · filed 2018-05-04 | $92.43M derived: sum of 2 quarters · filed 2018-05-04 | $128.01M derived: sum of 3 quarters · filed 2018-05-04 | $158.48M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | $43.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $79.14M derived: sum of 2 quarters · filed 2018-02-27 | $109.61M derived: sum of 3 quarters · filed 2018-02-27 | $124.90M 10-K · filed 2018-02-27 |
| 2017-09-30 | $35.58M 10-Q · filed 2017-11-07 | $66.05M derived: sum of 2 quarters · filed 2017-11-07 | $81.34M 10-Q · filed 2017-11-07 | $93.30M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $30.48M 10-Q · filed 2017-08-08 | $45.76M 10-Q · filed 2017-08-08 | $57.72M derived: sum of 3 quarters · filed 2018-05-04 | $62.99M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $15.29M 10-Q · filed 2018-05-04 | $27.25M derived: sum of 2 quarters · filed 2018-05-04 | $32.52M derived: sum of 3 quarters · filed 2018-05-04 | $32.61M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $11.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $17.23M derived: sum of 2 quarters · filed 2018-02-27 | $17.33M derived: sum of 3 quarters · filed 2018-02-27 | $17.33M 10-K · filed 2018-02-27 |
| 2016-09-30 | $5.27M 10-Q · filed 2017-11-07 | $5.37M derived: sum of 2 quarters · filed 2017-11-07 | $5.37M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $97.00K 10-Q · filed 2017-08-08 | $97.00K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |